吲达帕胺分别联用3种降压药治疗2级原发性高血压的疗效和安全性比较

发布时间：2018-05-28 22:36

本文选题：吲达帕胺 + 贝那普利　；参考：《中国药房》2017年21期

【摘要】：目的:比较吲达帕胺分别联合贝那普利、厄贝沙坦、氨氯地平治疗2级原发性高血压(EH)的疗效和安全性。方法:150例2级EH患者随机分为贝那普利组(50例)、厄贝沙坦组(50例)和氨氯地平组(50例)。3组患者均给予吲达帕胺片2.5 mg,口服,每日1次。在此基础上,贝那普利组患者口服盐酸贝那普利片10 mg,每日1次;厄贝沙坦组患者口服厄贝沙坦片150 mg,每日1次;氨氯地平组患者口服氨氯地平片5 mg,每日1次。3组疗程均为12周。观察3组患者治疗前后收缩压、舒张压、心率、总胆固醇(TC)、三酰甘油(TG)、血钾水平及不良反应发生情况。结果:贝那普利组、厄贝沙坦组和氨氯地平组患者总有效率比较,差异无统计学意义(90.0%vs.88.0%vs.92.0%,P0.05)。治疗前,3组患者收缩压、舒张压、心率、TC、TG、血钾水平比较,差异均无统计学意义(P0.05)。治疗后,3组患者收缩压、舒张压均显著低于同组治疗前,差异均有统计学意义(P0.05);但3组间比较差异均无统计学意义(P0.05)。3组患者治疗前后心率、TC、TG及贝那普利组、厄贝沙坦组治疗前后血钾比较,差异均无统计学意义(P0.05)。氨氯地平组患者血钾水平显著低于同组治疗前,差异有统计学意义(P0.05)。厄贝沙坦组患者不良反应发生率显著低于贝那普利组和氨氯地平组,差异有统计学意义(P0.05),但贝那普利组与氨氯地平组间比较,差异无统计学意义(P0.05)。结论:吲达帕胺分别联合贝那普利、厄贝沙坦、氨氯地平治疗2级EH的疗效相当,但厄贝沙坦组的安全性优于贝那普利组和氨氯地平组。
[Abstract]:Aim: to compare the efficacy and safety of indapamide combined with benazepril irbesartan and amlodipine in the treatment of grade 2 essential hypertension. Methods one hundred and fifty patients with grade 2 EH were randomly divided into benazepril group (n = 50) and irbesartan group (n = 50) and amlodipine group (n = 50) were treated with indapamide 2.5 mg orally once a day. On this basis, benazepril group took 10 mg benazepril hydrochloride once a day, irbesartan group 150 mg of irbesartan tablets once a day. Amlodipine group was treated with amlodipine tablets (5 mg) once a day for 12 weeks. Systolic blood pressure, diastolic blood pressure, heart rate, total cholesterol TCU, triglyceride TGN, serum potassium level and adverse reactions were observed before and after treatment. Results: the total effective rate of benazepril group, irbesartan group and amlodipine group was not significantly different from that of benazepril group, irbesartan group and amlodipine group. There was no significant difference in the total effective rate of benazepril group, irbesartan group and amlodipine group. There was no significant difference in systolic blood pressure, diastolic blood pressure, heart rate, TCU TGand serum potassium levels between the three groups before treatment (P 0.05). After treatment, systolic blood pressure and diastolic blood pressure in the three groups were significantly lower than those in the same group before and after treatment, and the differences were statistically significant (P 0.05), but there was no significant difference between the three groups in heart rate TCTG and benazepril before and after treatment. In irbesartan group, there was no significant difference in serum potassium before and after treatment (P 0.05). The serum potassium level in amlodipine group was significantly lower than that in the same group before treatment (P 0.05). The incidence of adverse reactions in irbesartan group was significantly lower than that in benazepril group and amlodipine group (P 0.05), but there was no significant difference between benazepril group and amlodipine group. Conclusion: the efficacy of indapamide combined with benazepril irbesartan and amlodipine in the treatment of grade 2 EH is similar but the safety of irbesartan group is better than that of benazepril group and amlodipine group.
【作者单位】：广西壮族自治区桂东人民医院内科;
【分类号】：R544.11

【参考文献】